<DOC>
	<DOCNO>NCT01351987</DOCNO>
	<brief_summary>To analyze change International Prostate Symptom Score ( IPSS ) serum prostate-specific antigen ( PSA ) level baseline .</brief_summary>
	<brief_title>An Observational Study Dutasteride Alpha-blocker Combination Therapy Men With Symptomatic Benign Prostatic Hyperplasia PSA Level Over 4 ng/mL</brief_title>
	<detailed_description>This non-interventional , observational multicenter study . When subject allow dutasteride α-blocker orally daily two year investigator 's prescription . They invite observational study . All eligible subject allow prior alpha blocker therapy . Details acute urinary retention ( AUR ) BPH-related prostatic surgery episode record every visit . Subjects return clinic assessment every 3 month week 96 . The efficacy safety combine 5α-reductase inhibitor ( 5ARI ) , dutasteride , α-blocker assess .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Dutasteride</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Males , age ≧ 50 year Clinical diagnosis BPH medical history physical examination , include digital rectal examination ( DRE ) IPSS score ≧ 8 point prostate volume ≧ 30 mL Total serum PSA ≧ 4.0 ng/mL ≦ 20 ng/mL screen Previous TRUSguided biopsy do benign finding prostate cancer ( CaP ) detect within past 6 month . Dutasteride combination therapy allow investigator 's prescription Ability understand willingly provide write informed consent History evidence prostate cancer high grade prostatic intraepithelial neoplasia ( HGPIN ) With symptomatic urinary tract prostate infection urinary retention within 3 month prior entry study Use finasteride within 6 month screen visit Use dutasteride within 12 month screen visit</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Benign Prostatic Hyperplasia</keyword>
</DOC>